CogState logo

CGS - CogState Share Price

A$0.9 0.0  0.0%

Last Trade - 19/04/21

Small Cap
Market Cap £85.7m
Enterprise Value £73.8m
Revenue £20.1m
Position in Universe 721st / 1898
Unlock CGS Revenue
Relative Strength (%)
1m -6.62%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
13.5 19.9 26.5 29.0 21.9 23.7 27.4 35.6 +12.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, CogStateLimited revenues increased 59% to $13.9M. Net lossdecreased 84% to $448K. Revenues reflect Clinical Trialssegment increase of 52% to $12.6M. Lower net loss reflectsTravel Expense decrease from $284K (expense) to $50K(income), Stock-based Compensation in SGA decrease from$18K (expense) to $145K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CGS Revenue Unlock CGS Revenue

Net Income

CGS Net Income Unlock CGS Revenue

Normalised EPS

CGS Normalised EPS Unlock CGS Revenue

PE Ratio Range

CGS PE Ratio Range Unlock CGS Revenue

Dividend Yield Range

CGS Dividend Yield Range Unlock CGS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CGS EPS Forecasts Unlock CGS Revenue
Profile Summary

Cogstate Limited is a cognitive science company delivering software and services. The Company's segments include cognitive testing in Clinical Trials; the precision recruitment market, the healthcare market, the sport market and administration. In the clinical trials market, the Company's technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. In the precision recruitment market, the technology is used as an online screening tool as part of the process of recruiting subjects in clinical trials. In the healthcare market, the technology and associated services are being developed as a tool for primary care physicians to assess cognitive decline. In the sport market, the technology and associated services are used to provide concussion management tools in sport.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated December 17, 1999
Public Since February 13, 2004
No. of Shareholders: 1,349
No. of Employees: 61
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 170,238,331
Free Float (0.0%)
Eligible for
CGS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CGS
Upcoming Events for CGS
Frequently Asked Questions for CogState
What is the CogState share price?

As of 19/04/21, shares in CogState are trading at A$0.9, giving the company a market capitalisation of £85.7m. This share price information is delayed by 15 minutes.

How has the CogState share price performed this year?

Shares in CogState are currently trading at A$0.9 and the price has moved by 0.161k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CogState price has moved by 92.76% over the past year.

What are the analyst and broker recommendations for CogState?

Of the analysts with advisory recommendations for CogState, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CogState is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will CogState next release its financial results?

CogState is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the CogState dividend yield?

CogState does not currently pay a dividend.

Does CogState pay a dividend?

CogState does not currently pay a dividend.

When does CogState next pay dividends?

CogState does not currently pay a dividend.

How do I buy CogState shares?

To buy shares in CogState you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CogState?

Shares in CogState are currently trading at A$0.9, giving the company a market capitalisation of £85.7m.

Where are CogState shares listed? Where are CogState shares listed?

Here are the trading details for CogState:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: CGS
What kind of share is CogState?

Based on an overall assessment of its quality, value and momentum, CogState is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CogState share price forecast 2021?

Shares in CogState are currently priced at A$0.9. At that level they are trading at 41.11% discount to the analyst consensus target price of 0.00.

Analysts covering CogState currently have a consensus Earnings Per Share (EPS) forecast of 0.0301587 for the next financial year.

How can I tell whether the CogState share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CogState. Over the past six months, the relative strength of its shares against the market has been -1.7%. At the current price of A$0.9, shares in CogState are trading at 5.53% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CogState PE Ratio?

The CogState PE ratio based on its reported earnings over the past 12 months is 0.508k. The shares are currently trading at A$0.9.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of CogState?

CogState's management team is headed by:

Martyn Myer - NEC
Brad O'Connor - CEO
Paul Maruff - OTH
Richard van den Broek - NID
Sophie Egholm - OTH
David Dolby - NED
Jason Sada - OTH
Abby Moore - OTH
Frank Cheng - CEX
Richard Mohs - NED
Ingrid Player - NID
Kenneth Billard - OTH
Chris Edgar - CSO
Darren Watson - CFO
Ben Bloomfield - CTO
Who are the major shareholders of CogState?

Here are the top five shareholders of CogState based on the size of their shareholding:

Australian Ethical Investment Ltd. Investment Advisor
Percentage owned: 17.24% (29.5m shares)
Dolby (Dagmar) Individual Investor
Percentage owned: 15.11% (25.8m shares)
Myer (Martyn Kenneth) Individual Investor
Percentage owned: 13.81% (23.6m shares)
FIL Investment Management (Hong Kong) Limited Investment Advisor
Percentage owned: 7.7% (13.2m shares)
Fidelity International Investment Advisor
Percentage owned: 6.92% (11.8m shares)
Similar to CGS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.